2010/12/17

Betaver

Release form, composition and packing Betaver 

Of white or nearly white, Valium, with a facet. 1 tab. betahistine dihydrochloride 8 mg Inactive ingredients: microcrystalline cellulose, lactose, corn starch, polyvinylpyrrolidone (povidone), sodium carboxymethyl starch (primogel), talc, colloidal silicon dioxide (Aerosil).

Of white or nearly white, Valium, Bevel and risks. 1 tab. betahistine dihydrochloride 16 mg. Excipients: microcrystalline cellulose, lactose, corn starch, polyvinylpyrrolidone (povidone), sodium carboxymethyl starch (primogel), talc, colloidal silicon dioxide (Aerosil).

Clinico-pharmacological group: drug improving the microcirculation of the labyrinth that is used in the pathology of the vestibular apparatus.

Pharmacological action

Synthetic analogue of histamine. Acts primarily on the histamine H1-and H3-receptors of the inner ear and vestibular nuclei of the CNS. By direct agonistic effects on histamine H1-receptors in blood vessels of the inner ear, as well as indirectly through effects on the histamine H3-receptors improves microcirculation and capillary permeability of the inner ear, normalizes blood pressure of the endolymph in the labyrinth and cochlea. Along with that betahistine increases blood flow to the basilar artery. Possesses a strong central effect, as an inhibitor of histamine H3-receptors of the vestibular nerve nuclei.

Normalizes conduction in neurons of the vestibular nuclei at the brainstem. Clinical manifestations of these properties are to reduce the frequency and intensity of vertigo, noise reduction and tinnitus, improvement of hearing in the case of his slides.

Pharmacokinetics

Absorption and distribution after oral betahistine dihydrochloride rapidly and almost completely absorbed from the gastrointestinal tract. Cmax in plasma is reached after 3 h. Plasma protein binding is low.

Breeding

T1 / 2 of 3-4 hours almost completely excreted by the kidneys as metabolites (2-peridiluksusnoy acid) for 24 h.

Statement
treatment and prophylaxis of vestibular vertigo of various origins;
syndromes characterized by dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting;
disease and Meniere's syndrome.

Dosing regimen

Drug is prescribed inside during the meal. Improving the condition stated in the beginning of therapy. Stable therapeutic effect is achieved within 2 weeks of taking the drug and may increase when taking the drug for several months. Duration of therapy set individually.

Side effect

Probably: violations of the gastrointestinal tract. In very rare cases: cutaneous manifestations of allergic reactions (skin rash, itching, hives), angioedema.

Contraindications
pregnancy;
Lactation (breastfeeding);
hypersensitivity to the drug.

Precautions should be prescribed the drug to patients with gastric ulcer or duodenal ulcer (including history), patients with pheochromocytoma and bronchial asthma.

Pregnancy and lactation

Insufficient data to assess the impact of the drug during pregnancy and lactation, so its use is contraindicated in those periods.

Cautions

During treatment, patients with gastric ulcer or duodenal ulcer, with pheochromocytoma, with asthma should be under medical supervision. Effects on ability to drive vehicles and management mechanisms Betaver has no sedative effect and does not affect ability to drive vehicles or operate machinery.

Overdose

Symptoms: nausea, vomiting when receiving a dose exceeding 640 mg may cause seizures.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Drug Interactions

Drug interactions drug Betaver with other drugs has not been described. Incompatibilities are unknown.

Conditions and terms of

List B. The drug should be stored in a dry place, protected from light, place inaccessible to children at or above 25 ° C. Shelf life - 2 years.